Barrett's esophagus and esophageal adenocarcinoma: A practical approach to diagnosis and management

Annals of Long-Term Care

Volumn 10, Issue 10, 2002, Pages 27-31

  Gopal, Deepak V ^a,c   Powers, Jason ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b KAISER PERMANENTE   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTON PUMP INHIBITOR;

ADJUVANT CHEMOTHERAPY; AGING; BARRETT ESOPHAGUS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENDOSCOPY; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; HUMAN; PREVALENCE; REFLUX ESOPHAGITIS; REVIEW; SURVIVAL RATE;

EID: 0036819823     PISSN: 15247929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Falk GW. Barrett's esophagus. Clinical Perspectives in Gastroenterology 2001;Sept/Oct:267-275.
2. Morales TG, Sampliner RE. Barrett's esophagus: Update on screening, surveillance, and treatment. Arch Intern Med 1999;59:1411-1416.
3. Cameron AJ, Lomboy CT. Barrett's esophagus: Age, prevalence, and extent of columnar epithelium. Gastroenterology 1992;103(4):1241-1245.
4. Gopal DV. Another look at Barrett's esophagus: Current thinking on screening and surveillance strategies. Postgrad Med 2001;110(3):57-68.
5. Gopal DV, Faigel DO, Magaret N, et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): Results from multicenter consortium [abstract]. Gastroenterology 1999;116(4):A175.
6. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterologists. Am J Gastroenterol 1998;93(7):1028-1032.
7. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92(4):582-585.
8. Haag S, Nandurkar S, Talley NJ. Regression of Barrett's esophagus: The role of acid suppression, surgery, and ablative methods. Gastrointest Endosc 1999;50(2):229-240.
9. Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988;94(1):81-90.
10. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94(8):2043-1053.
11. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18(18):3199-3201.
12. Ellis FH Jr, Watkins E Jr, Krasna MJ, et al. Staging of carcinoma of the esophagus and cardia: A comparison of different staging criteria. J Surg Oncol 1993;52:231-235.
13. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. New Engl J Med 1996;35(7):462-467.